Promoter holding
64.27%
WP
Wardex Pharmaceuticals Private Limited - Due diligence report
A 360° intelligence report on Wardex Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gro…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Wardex Pharmaceuticals Private Limited — 360° Intelligence Report
Generated from MCA filings & public records75/100
Trust Score
Low Risk
Wardex Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 75/100. Wardex Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 1946, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 15 Aug 2026 from the latest processed filings. Wardex Pharmaceuticals Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
75/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
66/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Profitable - internal accruals available.
Charges position: 1 open (30.00 Lakh) · 3 satisfied (1.64 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Bnp Paribas | 1 | 48.0 cr |
| Banque Nationale De Paris | 1 | 48.0 cr |
| Catholic Syrian Bank Ltd. | 1 | 48.0 cr |
| Banque Natinale De Paris | 1 | 48.0 cr |
Compliance Score: 66/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (23 disclosure(s)).
- 14 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 55/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ERROL JAMES DESOUZA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAGDISH PURUSHOTTAMDAS MEHTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SYED ASIF RAZA RIZVI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VITALAPURAM RAJANGAM KRISHNA SUBRAMANIAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATRAMAN SUBRAMANIAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PASCAL POSTEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ALEXANDRE JOHAN PASCAL POSTEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 7 directors on the board.
- ERROL JAMES DESOUZA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
0 allotment(s) · 1 transfer(s)
| Group entity | Relationship | % held |
|---|---|---|
| Ward Pharmaceuticals Limited | Associate Company | 74.00% |
| Franco-indian Research Private Limited | Associate Company | 74.00% |
Key managerial personnel: ALEXANDRE JOHAN PASCAL POSTEL (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 80
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 79+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.56 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment76/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 30.00 Lakh already registered.
- Compliance gaps should be priced into terms.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events22 Apr 2025
Charge satisfied
Bnp Paribas
Charge satisfied
Banque Nationale De Paris
Charge satisfied
Banque Natinale De Paris
28 Jan 2025
Director appointed
ERROL JAMES DESOUZA (Additional Director)
27 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
10 Feb 2023
Director ceased
SUBHAGMAL MOHANCHAND DADHA
26 Nov 2021
Director ceased
SYED ASIF RAZA RIZVI
Director ceased
SHAHIDA PASCAL POSTEL
Director ceased
PASCAL POSTEL
31 Mar 2021
Share transfer (FY 2021)
2048.00000000 shares to MADHU DADHA
26 Feb 2021
Director appointed
SYED ASIF RAZA RIZVI (Director)
23 Feb 2021
Director ceased
NOEL CHRISTOPHER AMANNA
31 Dec 2020
Director appointed
PASCAL POSTEL (Director)
28 Sep 2018
Director ceased
VENKATRAMAN SUBRAMANIAM
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Net worth is positive.
7 active director(s) / partner(s); review board churn before relying on management continuity.
14 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Jackson Laboratories | U24230PB1986PTC007168 | Punjab, Punjab, India |
| G.T.Products | U15495TN2002PTC049130 | Chennai, Tamil Nadu, India |
| Kekule Pharma Limited | U24231TG1984PLC005145 | Hyderabad, Telangana, India |
| Pulse Pharmacy | U24239TG1997PTC026151 | Hyderabad, Telangana, India |
| Ideal Detonators Private Limited | U24292TG1989PTC010513 | Secunderabad, Telangana, India |
| Bakson'S Homoeopathic | U74899DL1989PTC036300 | New Delhi, Delhi, India |
| Vision Drugs | U99999TG2005PTC048204 | Shaikpet, Telangana, India |
| Indian Toners & Developers | L47613UP1990PLC015721 | Up, Uttar Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Wardex Pharmaceuticals Private Limited before audits and certifications: compliance score 66/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Wardex Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Wardex Pharmaceuticals Private Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 75/100, distress signals and MSME payment-delay disclosures - know whether Wardex Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Wardex Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Wardex Pharmaceuticals Private Limited an active company?
Wardex Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 66/100 (Moderate).
Is Wardex Pharmaceuticals Private Limited financially healthy?
Wardex Pharmaceuticals Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Wardex Pharmaceuticals Private Limited?
Its overall Trust Score is 75/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Wardex Pharmaceuticals Private Limited?
See the directors and ownership sections above for board and shareholding detail. 7 active director(s) are on record.
Does Wardex Pharmaceuticals Private Limited have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.
Is Wardex Pharmaceuticals Private Limited up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 66/100 (Moderate).
Is it risky to lend to Wardex Pharmaceuticals Private Limited?
Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
